992O - FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
| Autor: | Moore, K., Oza, A., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Farias-Eisner, R., Banerjee, S., Murphy, C., Tanyi, J., Hirte, H., Konner, J., Lim, P., Hayes, M Prasad, Monk, B., Kim, S., Wang, J., Pautier, P., Vergote, I., Birrer, M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v403-v403 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|